← Back to Calendar

zovegalisib (RLY-2608)

Relay Therapeutics · $RLAY
Standard Review Phase 2 Fast Track Breakthrough Therapy
Catalyst Date
May 15, 2026
Time Remaining
32 days
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 3m ago · Data: FMP
Current Price
$14.94 +572.97%
+$12.72 today
Day: $14.51 – $15.42
Market Cap
N/A
Shares out: 178.73M
Float: 93.67M
52-Week Range
$2.30
$15.42
Current price is at 96% of 52-week range
Avg Volume
2.77M
Beta
1.58
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RLAY catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

PIK3CA-mutant HR+/HER2- metastatic breast cancer

Key Notes

SERENA-PI3K trial Phase 2 readout. Previously called RLY-2608; renamed zovegalisib after FDA Breakthrough Therapy designation. Initial Phase 1/2 data at ESMO TAT March 16, 2026 (presented). Full Phase 2 readout at ASCO 2026 expected. Breast cancer triplet data and frontline Phase 3 plans also expected in 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar